T1	Participants 368 417	30 subjects, between the ages of 8 and 18 with AD
T2	Participants 962 979	risperidone group
T3	Participants 1341 1359	haloperidol group.
T4	Participants 1255 1273	risperidone group,
T5	Participants 1578 1589	Risperidone
T6	Participants 1626 1637	haloperidol
